US CELLULAR ($USM) posted quarterly earnings results on Friday, May 2nd. The company reported earnings of $0.21 per share, missing estimates of $0.35 by $0.14. The company also reported revenue of $891,000,000, missing estimates of $941,831,565 by $-50,831,565.
You can see Quiver Quantitative's $USM stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
US CELLULAR Hedge Fund Activity
We have seen 65 institutional investors add shares of US CELLULAR stock to their portfolio, and 59 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- THIRD POINT LLC removed 545,344 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $34,203,975
- MILLENNIUM MANAGEMENT LLC removed 263,756 shares (-49.4%) from their portfolio in Q4 2024, for an estimated $16,542,776
- ALYESKA INVESTMENT GROUP, L.P. added 204,146 shares (+73.9%) to their portfolio in Q4 2024, for an estimated $12,804,037
- BRIDGEWAY CAPITAL MANAGEMENT, LLC removed 153,248 shares (-70.9%) from their portfolio in Q4 2024, for an estimated $9,611,714
- CITADEL ADVISORS LLC removed 111,123 shares (-20.3%) from their portfolio in Q4 2024, for an estimated $6,969,634
- UBS GROUP AG added 66,867 shares (+265.5%) to their portfolio in Q4 2024, for an estimated $4,193,898
- MAN GROUP PLC added 63,501 shares (+124.6%) to their portfolio in Q4 2024, for an estimated $3,982,782
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
US CELLULAR Analyst Ratings
Wall Street analysts have issued reports on $USM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Raymond James issued a "Outperform" rating on 11/07/2024
To track analyst ratings and price targets for US CELLULAR, check out Quiver Quantitative's $USM forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
